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ABSTRACT
Background Symptoms of advanced hepatocellular 
carcinoma (HCC) represent a substantial burden for the 
patient and are important endpoints to assess when 
evaluating treatment. Patient- reported outcomes were 
evaluated in subjects with advanced HCC and baseline 
alpha- fetoprotein (AFP) ≥400 ng/mL treated with second- 
line ramucirumab.
Patients and methods Patients with AFP≥400 ng/mL 
enrolled in the REACH or REACH-2 phase 3 studies were 
used in this analysis. Eligible patients had advanced 
HCC, Child- Pugh A, Eastern Cooperative Oncology Group 
performance status 0/1 and prior sorafenib. Patients 
received ramucirumab 8 mg/kg or placebo once every 
2 weeks. Disease- related symptoms and health- related 
quality of life (HRQoL) were assessed with the Functional 
Assessment of Cancer Therapy Hepatobiliary Symptom 
Index (FHSI)-8 and EuroQoL-5- Dimensions (EQ- 5D) 
instruments, respectively. Time to deterioration (TTD) 
(≥3- point decrease in FHSI-8 total score;≥0.06- point 
decrease in EQ- 5D score, from randomisation to first date 
of deterioration) was determined using Kaplan- Meier 
estimation and the Cox proportional hazards model. Both 
separate and pooled analyses for REACH AFP≥400 ng/mL 
and REACH-2 patients were conducted.
Results In the pooled population with AFP ≥400 ng/
mL (n=542; ramucirumab, n=316; placebo, n=226), 
median TTD in FHSI-8 total score was prolonged with 
ramucirumab relative to placebo (3.3 vs 1.9 months; HR 
0.725; (95% CI 0.559 to 0.941); p=0.0152), including 
significant differences in back pain (0.668; (0.497 to 
0.899); p=0.0044), weight loss (0.699; (0.505 to 0.969); 
p=0.0231) and pain (0.769; (0.588 to 1.005); p=0.0248) 
symptoms. TTD in EQ- 5D score was not significantly 
different between ramucirumab and placebo groups 
(median 2.9 vs 1.9 months). Results in the individual trials 
were consistent with these findings.
Conclusions Ramucirumab in second- line treatment 
of advanced HCC demonstrates consistent benefit in the 
delay of deterioration in disease- related symptoms with no 
worsening of HRQoL. Taken with previously demonstrated 
ramucirumab- driven survival benefits in this setting, these 
data may inform patient–clinician discussions about the 
benefit–risk profile of this therapy.
Trial registration number NCT01140347; NCT02435433, 
NCT02435433.
INTRODUCTION
Hepatocellular cancer (HCC) represents 
the fourth most common cause of cancer- 
related mortality globally.1 2 Patients with 
HCC frequently present at an advanced 
stage, when prognosis is poor and treatment 
Key questions
What is already known about this subject?
 ► Ramucirumab has previously demonstrated both 
efficacy and tolerability as a second- line systemic 
treatment in patients with advanced HCC in two 
phase 3 studies (REACH and REACH-2).
 ► Data on patient- reported quality- of- life outcomes 
in the second- line setting among patients with ad-
vanced HCC is limited.
What does this study add?
 ► Time to deterioration in disease symptoms (mea-
sured by the Functional Assessment of Cancer 
Therapy Hepatobiliary Symptom Index) was signifi-
cantly delayed in patients treated with ramucirumab 
versus placebo.
 ► Significant differences in time to deterioration for 
back pain, weight loss and pain were observed.
 ► Delay in deterioration of these cancer- related symp-
toms extends the previously demonstrated benefit of 
ramucirumab to survival.
How might this impact on clinical practice?
 ► By demonstrating the potential for second- line ra-
mucirumab to address both the symptoms and 
HRQoL of patients with HCC, our results will help to 
guide patient–clinician discussions about the risks 
and benefits of this therapy.
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options are limited. Notably, patients with advanced HCC 
often report a complex variety of symptoms, related to 
the cancer itself, underlying cirrhosis and other comorbid 
conditions and side effects of treatment.3 HCC symp-
toms represent a substantial physiological and psycho-
logical burden for patients and can significantly affect 
their health- related quality of life (HRQoL).3 Primary 
endpoints in clinical trials of new therapies for advanced 
HCC primarily focus on improvements in overall survival 
(OS) and progression- free survival (PFS), but many of 
the gains observed to date have been relatively small.3 
In the non- curative setting, the symptoms and HRQoL 
experienced by patients with advanced HCC repre-
sent important endpoints to assess when evaluating the 
benefits of treatment.3 In the first- line HCC setting, two 
recent studies have examined patient- reported HRQoL 
outcomes,4 5 however, data in the second- line setting are 
limited.
Ramucirumab, a human IgG1 monoclonal antibody that 
inhibits ligand activation of vascular endothelial growth 
factor receptor-2, has demonstrated both efficacy and 
tolerability as a second- line systemic treatment in patients 
with advanced HCC and baseline alpha- fetoprotein 
(AFP) levels≥400 ng/mL in two phase 3 studies (REACH 
and REACH-2).6 7 Further analysis of the REACH study 
demonstrated that in the subgroup with elevated AFP, 
the rate of deterioration of patients’ symptoms was 
significantly reduced.8 More recently, the REACH-2 trial, 
a follow- up study in patients with advanced HCC and 
elevated baseline AFP, confirmed the results from the 
REACH trial.7 In the current study, we sought to further 
assess the effects of ramucirumab on patient- reported 
outcomes (PROs), including HCC- related symptoms and 
HRQoL. To obtain a general estimate of treatment effect 
from a larger patient population, we examined PROs in 
the population of patients with baseline AFP ≥400 ng/mL 
pooled from the REACH and REACH-2 studies, in addi-
tion to confirming the consistency between the individual 
study populations. By investigating the impact of ramu-
cirumab on PROs for patients with advanced HCC, we 
hope to demonstrate the effect of ramucirumab on addi-
tional outcomes that are important to both patients and 
clinicians while underscoring the value of considering 
such outcomes in studies that investigate novel agents for 
patients with advanced HCC.
METHODS
Patients
Patient populations in REACH (NCT01140347; 
NCT02435433) and REACH-2 (NCT02435433) have 
been previously described in detail.6 7 Eligible patients 
had advanced HCC, Child- Pugh score <7 (Class A only), 
Eastern Cooperative Oncology Group performance 
status (ECOG PS) score of 0 or 1, Barcelona Clinic Liver 
Cancer stage C or B and prior sorafenib (discontinued 
due to progression or intolerance). REACH patients in 
the current analysis were from a protocol- defined patient 
subpopulation with baseline AFP ≥400 ng/mL; REACH-2 
patients were required to have a baseline AFP ≥400 ng/
mL. All patients provided written, informed consent.
Study design
REACH and REACH-2 were global, double- blind, 
randomised, placebo- controlled phase 3 trials with similar 
protocol procedures, efficacy assessments and treatment 
regimens.6 7 Patients were randomised (1:1 REACH and 
2:1 REACH-2) to receive ramucirumab 8 mg/kg or placebo 
intravenously once every 2 weeks until disease progres-
sion, unacceptable toxicity or withdrawal of consent. All 
patients in both treatment arms received best supportive 
care, as determined by the treating clinician(s), including 
concomitant treatments to address symptoms and side 
effects (online supplementary table S1) and palliative 
care consultation (data not summarised).
Patient-reported outcomes
Two patient- reported instruments were administered: 
the Functional Assessment of Cancer Therapy (FACT) 
Hepatobiliary Symptom Index (FHSI-8) and EuroQoL 
5- Dimensions (EQ- 5D). The FHSI-8 is a self- administered 
questionnaire used to assess the most frequent and 
concerning symptoms experienced by patients with 
hepatobiliary malignancies (lack of energy, nausea, 
pain, weight loss, back pain, fatigue, jaundice, stomach 
pain or discomfort).9–11 Each symptom was assessed 
using a 5- point response scale (from ‘not at all’ to ‘very 
much’), and scores were reversed and used to compute 
a total score (range 0–32), as per instrument guidelines, 
where a higher score represents lower symptom burden. 
The EQ- 5D is a generic instrument for assessment of the 
effects of disease and treatment on HRQoL across many 
different disease states. The EQ- 5D descriptive system 
comprises five dimensions (mobility, self- care, usual activ-
ities, pain/discomfort, anxiety/depression), each with 3 
levels of severity, used in the derivation of an overall index 
score (where 1 represents best possible health; 0, death).12 
EQ- 5D index scores were used in REACH whereas a 
version of the EQ- 5D with five severity levels (EQ- 5D- 5L) 
was used in REACH-2. For consistency, EQ- 5D- 5L scores 
were transformed to EQ- 5D with the EQ- 5D- 5L cross-
walk13 in the current analyses. Minimally important differ-
ences (MIDs) have been reported as 2–3 points for the 
FHSI-8 total score,14 and 0.06–0.08 points for the EQ- 5D 
index score in all cancers.15 We have further conducted a 
psychometric analysis of REACH-2 data, which supported 
a 3- point meaningful change threshold for FHSI-8 total 
score in our trial population (data on file). We use these 
MIDs herein as criteria for clinically meaningful changes.
We administered the two surveys together at the same 
time points throughout both studies, administering the 
FHSI-8 first. We collected the surveys at baseline and end 
of treatment. In REACH, we also collected data at the start 
of cycles 4, 10 and 16 (ie, at 6 weeks following first treat-
ment and every 12 weeks thereafter). In REACH-2, we 
collected data every 6 weeks. Following discontinuation 
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from study therapy, the end- of- treatment visit occurred 
within 7 days, with PROs collected at that time.
Statistical analyses
We performed a pooled data analysis for REACH (AFP 
≥400 ng/mL) and REACH-2 by pooling together indi-
vidual patient data from the two studies and analysing 
with stratification by study to account for clustering of 
patients within each study. Pooled analyses were prespeci-
fied prior to REACH-2 database lock. We calculated survey 
compliance as the percentage of completed assessments 
among the number of expected assessments (patients still 
on study without progression). We present descriptive 
statistics as mean±SD at baseline and at end of treatment 
for FHSI-8 total scores and EQ- 5D index scores: infer-
ential statistics were not performed as these data were 
confounded due to differential survival times in the two 
treatment groups and are subject to statistical concerns 
of nonrandom missing data. To mitigate concerns of bias 
associated with nonrandom missing data, time to first 
deterioration (TTD) was compared between treatment 
arms in FHSI-8 total and EQ- 5D index scores with TTD 
prespecified as the time from the randomisation date to 
the first date with a clinically meaningful≥3- point and 
≥0.06- point decrease from baseline, respectively.14 15 The 
TTD of each FHSI-8 symptom was compared between 
treatment arms with deterioration threshold prespecified 
as a decrease in one categorical response for an individual 
item. Patients who did not experience a deterioration 
were censored at the last assessment in TTD analyses. We 
estimated the TTD curves and medians using the Kaplan- 
Meier method. P values for treatment comparisons were 
derived from the log- rank test. A two- sided p<0.05 was 
considered statistically significant. We calculated HRs 
with 95% CI using a univariate Cox regression model. 
The individual studies were stratified by randomization 
stratification factors (REACH: aetiology; geographical 
region; REACH-2: macrovascular invasion; ECOG PS 0 vs 
1; geographical region). The impact of missing data on 
the TTD analysis of FHSI-8 total scores was evaluated via a 
sensitivity analysis with missing data imputed by multiple 
imputation using Markov Chain Monte Carlo method-
ology on the REACH-2 analysis population, conducted as 
detailed above for the original analyses.
RESULTS
The pooled analysis population included 542 patients 
(ramucirumab, n=316; placebo, n=226). Of these, 250 
patients originated from REACH (ramucirumab, n=119; 
placebo, n=131) and 292 originated from REACH-2 
(ramucirumab, n=197; placebo, n=95; table 1). At the time 
of data cut- off in each study, most patients were off treat-
ment (ramucirumab, 94%–98%; placebo, 98%–100%), 
with the majority in both treatment groups discontinuing 
due to disease progression (ramucirumab, 69%–70%; 
placebo, 81%–87%; online supplementary figure S1). 
Demographics and baseline clinical characteristics were 
balanced between the treatment groups in each of the 
three analysis populations except median baseline AFP 
levels were slightly imbalanced at the per- study level 
(REACH (AFP ≥400 ng/mL): ramucirumab, 5293 ng/
mL; placebo, 7022 ng/mL; REACH-2 ramucirumab, 
3920 ng/mL; placebo, 2741 ng/mL); however, this was 
not observed once the data were pooled (ramucirumab, 
4102 ng/mL; placebo, 4048 ng/mL; table 1).
We observed similar compliance with the FHSI-8 and 
EQ- 5D instruments across the two treatment groups in all 
analysis populations, with rates of ≥95% at baseline and 
≥65% at end of treatment (online supplementary table S2; 
Chau et al).8 In the pooled population, the TTD in HCC 
symptoms based on total FHSI-8 scores was prolonged 
for patients assigned to ramucirumab compared with 
patients assigned to placebo (median 3.3 vs 1.9 months, 
respectively; HR 0.725; 95% CI, 0.559 to 0.941; p=0.0152; 
figure 1A). The findings from the individual study popu-
lations were consistent with the pooled data although the 
differences between treatment groups for TTD in FHSI-8 
total scores did not reach statistical significance (ramu-
cirumab vs placebo: REACH (AFP ≥400 ng/mL) median 
2.9 vs 1.6 months; HR 0.690; 95% CI 0.470 to 1.014; 
p=0.054; Online supplementary figure S2A; REACH-2 
median 3.7 vs 2.8 months; HR 0.799; 95% CI 0.545 to 
1.171; p=0.2382; figure 1B). We observed similar find-
ings in the sensitivity analysis on the REACH-2 cohort 
(ramucirumab: median 3.0 months; placebo: median 
2.8 months; HR 0.816; 95% CI 0.572 to 1.163; p=0.2610), 
indicating that missing data did not have a statistical 
impact on the TTD analysis. Sensitivity analyses of FHSI-8 
outcomes in REACH also found no effect of missing data 
on the overall findings.8
For the individual FHSI-8 symptom items (figure 2A; 
figure 3A–H), in the pooled population, we found statis-
tically non- significant delays in the time to deteriora-
tion for symptoms of nausea and fatigue and statistically 
significant delays in TTD for the symptoms of weight loss 
(ramucirumab: median 6.0 months; placebo: median 3.3 
months; HR 0.699; 95% CI, 0.505 to 0.969; p=0.0231), pain 
(ramucirumab: median 4.2 months; placebo: median 2.6 
months; HR 0.769; 95% CI, 0.588 to 1.005; p=0.0248), and 
back pain (ramucirumab: median 5.7 months; placebo: 
median 2.8 months; HR 0.668; 95% CI, 0.497 to 0.899; 
p=0.0044; figure 3C–E). The REACH (AFP ≥400 ng/mL) 
subpopulation also demonstrated a correlation between 
ramucirumab and improved symptoms, with the most 
notable being delayed worsening of pain (ramucirumab: 
median 3.3 months; placebo: median 1.8 months; HR 
0.635; 95% CI 0.422 to 0.955, p=0.0259; Online supple-
mentary figure S2B). Similarly, in REACH-2, we found 
patients assigned to ramucirumab experienced delays to 
symptom worsening for the symptoms of nausea, pain, 
back pain, weight loss and fatigue, although back pain 
was the only individual symptom to reach significance 
for prolonged TTD (ramucirumab: median 6.5 months; 
placebo: median 2.9 months; HR 0.542 95% CI 0.350 to 
0.838; p=0.0052; figure 2B).
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In the pooled population, the TTD in HRQoL based on 
the EQ- 5D index score was not significantly different for 
patients assigned to ramucirumab (median 2.9 months) 
compared with patients assigned to placebo (median 
1.9 months; HR 0.858; 95% CI 0.662 to 1.111; p=0.2485; 
online supplementary figure S3A). A delay in TTD with 
ramucirumab treatment was observed in the REACH-2 
population, but the difference between treatment groups 
did not reach significance (median ramucirumab: 4.2 
months; placebo: 2.9 months; HR 0.811; 95% CI 0.543 to 
1.211; p=0.2898; online supplementary figure S3B).
In the pooled and REACH-2 populations, patients in 
both arms reported clinically meaningful decreases from 
baseline in total FHSI-8 score and EQ- 5D at end of treat-
ment (online supplementary table S3). In the REACH 
(AFP ≥400 ng/mL) population, for FHSI-8, only patients 
in the placebo treatment arm reported an average mean-
ingful decrease (mean change: ramucirumab: −2.21 
(±5.63); placebo: −3.73 (±5.88)) whereas the changes in 
EQ- 5D scores were similar in the two treatment groups 
(mean change: ramucirumab: −0.120 (±0.320); placebo: 
−0.191 (±0.297)).8 In both the REACH (AFP ≥400 ng/
mL)8 and REACH-2 populations (online supplementary 
table S4), FHSI-8 total scores were maintained over the 
course of treatment in both treatment groups, with scores 
declining only at end of treatment.
Figure 1 Time to first deterioration in FHSI-8 total score. Data shown are from (A) pooled and (B) REACH-2 populations. 
The curves and medians were estimated using the Kaplan- Meier method, HR (95% CI) was estimated using a Cox regression 
model. In case of no FHSI-8 deterioration, the subject was censored at the time of the last FHSI-8 recording. FHSI-8, 
Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index.
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DISCUSSION
The current analysis demonstrates that ramucirumab 
treatment is associated with a delay in the deterioration 
of disease- related symptoms in patients with advanced 
HCC and baseline AFP ≥400 ng/mL. In the pooled anal-
ysis of individual patient data from the study populations, 
comparison of TTD in disease- related symptoms based 
on FHSI-8 total score revealed a prolongation with single- 
agent ramucirumab compared with placebo. We also 
observed significant delays in deterioration for the indi-
vidual symptoms of weight loss, pain and back pain with 
ramucirumab. Taken together with previously published 
reports on OS and PFS benefits,6–8 these data highlight 
that second- line ramucirumab treatment has a significant 
benefit to both survival and cancer- related symptoms 
among patients with advanced HCC and elevated base-
line AFP.
Patients with advanced HCC often experience substan-
tial symptom burden and worsening of their HRQoL 
over time as the disease progresses or due to treatment- 
related toxicities or other complications.3 Our data 
demonstrate that mean FHSI-8 scores were maintained 
relative to placebo, while patients received ramucirumab, 
with significant declines observed primarily at the end- of- 
treatment visits in both ramucirumab and placebo groups. 
These data support the conclusion that the deterioration 
of symptoms occurred as a result of disease progression 
(the most common reason to end treatment) rather 
than due to treatment- associated toxicity. A relationship 
between deterioration of symptoms and disease progres-
sion is supported by the TTD analyses, which showed a 
significant delay in median TTD in FHSI-8 total score 
with ramucirumab compared with placebo, mirroring 
the improvements previously observed in PFS in patients 
with advanced HCC and elevated AFP.6 7 TTD in EQ- 5D 
index scores was not substantially different between treat-
ment groups, suggesting no worsening of HRQoL with 
ramucirumab treatment. As expected, the discrepancy 
observed is likely attributed to the sensitivity of instru-
ments, specifically that the FHSI-8 focuses on eight hepa-
tobiliary disease- specific symptoms,10 while the EQ- 5D is a 
generic non- disease- specific tool intended to complement 
other HRQoL measurement methods.12 Nevertheless, 
results on the FHSI-8 and EQ- 5D were consistent across 
all three analysis populations examined and are partic-
ularly noteworthy in the context of the historically poor 
Figure 2 Time to deterioration of FHSI-8 symptom items in patients in the (A) pooled; and (B) REACH-2 populations. Data 
in panel A are shown longitudinally in online supplementary figure S2. FHSI-8, Functional Assessment of Cancer Therapy 
hepatobiliary symptom index; N, number of patients in intent- to- treat population; N/A, not available (medians could not be 
calculated due to low number of events); RAM, ramucirumab.
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survival outcomes seen in advanced HCC. These findings 
are also in agreement with our previous demonstration of 
a linear relationship between the deterioration in FHSI-8 
total scores and change in tumour size in REACH8 and 
the current demonstration that ramucirumab has signif-
icant and clinically meaningful benefits in delaying the 
worsening in the symptoms of weight loss, pain and back 
pain, specific symptoms which have been related to HCC 
tumour burden.16 17
In the first- line HCC setting, two recent studies also 
reported improved PROs for the experimental arms, 
highlighting the relevance and importance of consid-
ering patient- reported HRQoL outcomes in HCC phase 
3 trials.4 5 These observations are relevant to the goal of 
therapy in this patient population, which is to extend 
survival while maintaining patients’ well- being, and 
underscore the need for further work that addresses the 
impact of new therapies on the symptoms and HRQoL of 
patients with advanced HCC. To date, no other second- 
line systemic agents have demonstrated similar benefits 
in terms of HCC symptoms, however, direct comparison 
is difficult due to use of different HRQoL measurement 
tools and interpretation of what constitutes meaningful 
benefit.18–20 Thus, our current findings represent a thor-
ough assessment of disease- specific symptoms in patients 
with advanced HCC and highlight the value of measuring 
cancer- related symptoms with PRO instruments in this 
patient population for which survival benefits of new 
treatments may be limited.
A strength of the current study is that REACH and 
REACH-2 had similar designs, assessments and treat-
ments, and the two studies observed consistent results 
in the relevant patient population with elevated baseline 
AFP. Further, these similarities allowed for pooling of 
REACH-2 and REACH (AFP ≥400 ng/mL) data, which 
enabled a better- powered assessment of ramucirumab 
treatment due to the larger dataset. In addition, compli-
ance in completing the PRO assessments was relatively 
high at end of treatment (>65%) despite the rapidly 
progressive nature of the disease, which could have influ-
enced the ability to collect data. However, the study had 
a number of limitations, common to studies of this type. 
Importantly, informative censoring bias was potentially a 
factor as, by study design, some PROs were not collected 
due to disease progression or death, when scores would 
be expected to be poor. In addition, patients had to meet 
the studies’ eligibility criteria, limiting the generalisability 
of these results to the broader patient population with 
advanced HCC. Further, in the current study, differences 
in the version of the EQ- 5D used in each study resulted 
in the need for converting the scores in order to combine 
them, and assessments were made at different times 
during the two studies, which precluded the pooling of 
some data for specific timepoint analyses. Additionally, 
the integrated analyses were not included in an a priori 
gate- keeping approach and, as such, are not controlled 
for multiple hypothesis testing. Finally, many other symp-
toms and concerns (eg, depression, anxiety, cognition) 
Figure 3 Longitudinal depiction of time to deterioration of FHSI-8 symptom items in patients with advanced hepatocellular 
carcinoma and baseline AFP ≥400 ng/mL. Data represent pooled individual patient data from REACH-2 and REACH (AFP 
≥400 ng/mL) populations. FHSI-8 symptom items included (A) lack of energy; (B) nausea; (C) pain; (D) weight loss; (E) back 
pain; (F) fatigue; (G) jaundice and (H) stomach pain or discomfort. The curves and medians were estimated using the Kaplan- 
Meier method, HR (95% CI) was estimated using a COX regression model. AFP, alpha- fetoprotein; FHSI-8, Functional 
Assessment of Cancer Therapy Hepatobiliary Symptom Index; N/A, medians could not be calculated due to low number of 
events.
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and important factors that can affect HCC symptom 
burden (eg, hospitalisations, concomitant medica-
tion usage, financial toxicity, physical function) are not 
reported here and should be explored in future work.
In conclusion, the current findings demonstrate that 
ramucirumab treatment is associated with a benefit in 
delaying the deterioration of disease- related symptoms 
and maintaining HRQoL in patients with advanced HCC 
and baseline AFP ≥400 ng/mL. By demonstrating the 
potential for second- line ramucirumab therapy to address 
both the symptoms and HRQoL of patients with HCC, 
our results have far- reaching implications to help guide 
patient- clinician discussions about the risks and benefits 
of this therapy.
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